Member Info for Soundsrisky

Sorry - should have said AT LEAST the highest price in last 12 months. Could (and should) be higher.

Am I correct that any offer to buy out needs to be at the highest price in the past 12 months? If so then that's 110p on 5th May last year. Same as last placing price too.....

@sileng under normal circumstances I would agree with you that it’s hard to suppress news, leaks happen and it becomes clear from SP action that something is happening. However, I have never seen a share so controlled as this with Algo’s all over it, managing every move, and so it’s possible that usual telltale signs are being suppressed too. Every day the continued silence from 4D makes it clearer in my mind that a buyout is currently being negotiated.

Hey Robins, I do completely understand your perspective. I was buying dddd at £1.40p + last year confident of it going to £3 or more …… then the market/NASDAQ/SO dive kicked in and it’s been mostly painful ever since. I agree that dddd could be worth so much more than £1.50p. My perspective is perhaps a bit different now. Due to lots of selling/trading/buying low my average is 41p and so £1.50 would see a decent return. I’m willing to let it go for that in the knowledge that funding from Merck or another big pharma would accelerate progress. I really do think dddd is potentially worth many £££. It’s simply my current perspective based on my average and wanting to see benefits for patients as soon as possible.

LBT’s

The funding will be taken care of by a takeover and will accelerate the science and research. If you care about getting these LBP’s to market it would be the best thing for all concerned.

Picking up.

They are indeed. For just a few £100m they can potentially make it more effective plus obtain 1000+ LBT patents and the market leader in the field. Definitely appealing I would say.

Very keen to get a job in 4D’s marketing department though. Literally paid for nothing over the past month or so. Hardly even so much as a tweet. Great work if you can get it : )

Without wanting to sound repetitive, every day that we are trading at these levels, particularly following recent oncology results, just makes it more likely that a buyout will occur. Just a matter of time and patience.

He’s a paid deramper. Doesn’t appear much, if at all, outside working hours. Gets about 20p per post that he gives to his mum to pay for lodging in her basement. A very sad individual, particularly when he/she will happily talk down a company that potentially has a treatment for cancer and other debilitating diseases.

Slightly surprised but bought again so all good. Would be nice to see some news, though the longer this quiet goes on the more I believe something big is happening in the background.

No, it’s back to $4 again. Enough negativity @leisurely.

LBPS looking better : )

Really is being held here in this range isn't it. Lots of 10k buys going through, someone building a position.

Looking good. Nice start to the week ; )

Still quiet eh 4D? Maybe a takeover RNS before US open then ; )

Potential for a takeover is VERY strong IMO;

Q1 Pharma Mergers & Acquisitions have been hotting up.
SP close to lows despite incredibly positive recent oncology data and safety profile of their LBP's. This makes 4D very vulnerable, and attractive.
Close ties already with Merck who report 23% rise in Keytruda sales in Q1 (4D's Mrx0518 seems to increase its effectiveness - potentially worth the buyout money on its own)
4D requiring funding at some point in the future - no urgency and I believe Oxford finance will support but good to get this resolved. Buyout would provide the funding to release the potential of the company.
Radio silence from DDDD for a month now (VERY unlike them recently) and this following the oncology result success - potentially bringing about acquisition talks?
If DDDD were planning a raise then they would be doing what they could to boost the share price, not let it languish, and not be talking about funding from Oxford finance in interview video's.
Merck (who, for obvious reasons, are the most likely buyer) gain control of 1000+ LBP patents in an area of medicine that is increasingly in focus and of interest.

Nobody can second guess Merck or another big pharma and I wouldn't claim to be able to do so either. However, regardless of that, its absolutely ridiculous that we are at 37p at present given the pipeline and oncology results. We could easily be 3 or 4 times that in a very short space of time even if no buyout. Upside far outweighs any potential downside, again all IMO.

To be fair. I might be being a bit harsh on @sang there. He at least has a brain, though not much integrity. @masturbates has neither.

Interesting. @sang and @masturbates pop up at the same time?! Might they be one in the same?